NCT06710847 - A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 13, 2024

Primary Completion Date

February 16, 2027

Study Completion Date

June 16, 2028

Conditions

Neoplasms, ColorectalSolid TumorColon CancerRectal CancerEndometrial Cancer

Interventions

DRUG

GSK4418959

GSK4418959 will be administered.

BIOLOGICAL

PD-1 inhibitor

PD-1 inhibitor will be administered.

Trial Locations (13)

3000

RECRUITING

GSK Investigational Site, Melbourne

10016

RECRUITING

GSK Investigational Site, New York

10408

RECRUITING

GSK Investigational Site, Gyeonggi-do

19104

RECRUITING

GSK Investigational Site, Philadelphia

19107

RECRUITING

GSK Investigational Site, Philadelphia

41404

RECRUITING

GSK Investigational Site, Daegu

48201

RECRUITING

GSK Investigational Site, Detroit

80218

RECRUITING

GSK Investigational Site, Denver

277-8577

RECRUITING

GSK Investigational Site, Chiba

411-8777

RECRUITING

GSK Investigational Site, Shizuoka

104-0045

RECRUITING

GSK Investigational Site, Tokyo

135-8550

RECRUITING

GSK Investigational Site, Tokyo

03080

RECRUITING

GSK Investigational Site, Seoul